Lupin the Indian pharmaceutical giant on Friday said that it has signed an agreement to obtain five brands, along with associated trademark rights, from the pharmaceutical company Menarini, the company said in a statement.  

The acquisition focuses on key therapy areas, including Gastroenterology, Urology, and Anti-infectives. Lupin has been marketing these brands - Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine), and Distaclor (Cefaclor) in the Indian market since July 2021, under a distribution and promotion agreement with A. Menarini India.

Nilesh Gupta, Managing Director of Lupin, emphasised the alignment of this acquisition with Lupin's strategic objectives, stating, "This acquisition aligns well with our strategic goal to broaden our presence in the Indian market. By offering a comprehensive range of products, our aim is to deliver even greater value to our stakeholders and the communities we serve."

Girisan Kariangal, Managing Director, Menarini India, stated, "Lupin has been successfully marketing the scope brands for Menarini since 2021, which has been a testament to our evolved collaboration. I am happy that Lupin will now carry forward its legacy with full trademark ownership. For Menarini, this transaction further signals our continued commitment to nurture and expand our Dermatology and Aesthetics portfolio and business."